Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.76
Bid: 5.02
Ask: 6.50
Change: -0.15 (-2.54%)
Spread: 1.48 (29.482%)
Open: 5.91
High: 0.00
Low: 0.00
Prev. Close: 5.91
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Arena soars on takeover; Accrol supply chain hit

Wed, 20th Oct 2021 10:56

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Arena Events Group PLC, up 43% at 20.30 pence, 12-month range 4.01p-21p. The firm - which services major events, supplying things such as temporary physical structures and seating - agrees to be taken over by Theta Bidco Ltd in deal worth enterprise value of GBP95.1 million. The suitor - owned by joint offerors IHC Industrial Holding LLC and Tasheel Holding Group LLC - will pay 21p per Arena share, being a 48% premium to Tuesday's closing price. It values Arena's entire issued share capital at GBP71.0 million. "IHC and Tasheel are both diversified holding companies, formed as part of initiatives to diversify and grow non-oil business sectors in the United Arab Emirates and Saudi Arabia respectively. Arena fits well into that diversification strategy, particularly given the growth potential of the temporary events structures market in the Middle East," they note.

----------

Reabold Resources PLC, up 19% at 0.1845p, 12-month range 0.15p-0.87p. Notes that Corallian Energy Ltd, in which it holds just under a 50% stake, has decided to undertake review of strategic options to maximise shareholder value. This will include fielding potential takeover offers for up to 100% of the firm. "Reabold remains supportive of Corallian, its board, and the timing of this strategic review. Reabold believes Corallian's flagship Victory gas development presents a compelling investment opportunity to any prospective investor," Reabold says.

----------

Real Good Food PLC, up 15% at 2.47p, 12-month range 1.42p-4.94p. The food manufacturer says revenue in six months to September 30 up 31% on a year ago and 0.7% above two years ago. Registers underlying earnings before interest, tax, depreciation and amortisation of GBP500,000 in period versus loss of GBP1.4 million a year ago. "We have made a good start to the year and the Group is well positioned for the seasonally busier second half of the year," says Executive Chair Mike Holt.

----------

Synairgen PLC, up 13% at 165.55p, 12-month range 74.8p-199.96p. The drug discovery and biotechnology company is informed that the external data safety monitoring board of the ACTIV-2 study has recommended that SNG001 advance into phase 3 in mild to moderate Covid-19 patients. "The advancement of SNG001 from phase 2 to phase 3 of the large ACTIV-2 trial is very welcome news and continues to build the case that our formulation of inhaled IFN-beta may have an important role in combatting CovidD-19 and future emerging virus threats," says Chief Executive Richard Marsden.

----------

AIM - LOSERS

----------

Accrol Group Holdings PLC, down 17% at 37.3p, 12-month range 33.50p-75.1p. The tissue converter notes "considerable" pressure on supply chains and higher costs, as well as shortage of HGV drivers restricting revenue growth. Says cost increases being successfully passed on, but there will be a time lag in passing on the full impact, resulting in earnings for financial year ending April 30 being "lower than previously expected".

----------

UK Oil & Gas PLC, down 7.5% at 0.1295p, 12-month range 0.1p-0.48p. Is "disappointed" by Isle of Wight Council's Planning Committee decision to refuse consent for the appraisal and testing of the Arreton oil and gas discovery. "Today's decision goes against last week's recommendation by the council's planning officers to approve the project. The company will now consider its position and whether to lodge an appeal with the Planning Inspectorate," it says.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
9 Sep 2020 12:23

Synairgen files for another patent on 'SNG001'

(Sharecast News) - Respiratory drug development company Synairgen updated the market on its intellectual property for the wholly-owned inhaled interferon beta asset 'SNG001' on Wednesday.

Read more
8 Sep 2020 19:32

IN BRIEF: Synairgen Reports Promising Findings From SNG001 Trial

IN BRIEF: Synairgen Reports Promising Findings From SNG001 Trial

Read more
8 Sep 2020 15:16

Synairgen upbeat on latest data from SNG001 trials

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced positive data from the interim analysis of its exploratory phase 2 clinical trial of inhaled 'SNG001' on Tuesday, in chronic obstructive pulmonary disease (COPD) patients with a confirmed respiratory viral infection.

Read more
21 Jul 2020 15:51

IN BRIEF: Synairgen Moving "Rapidly" To Get SNG001 Over Line

IN BRIEF: Synairgen Moving "Rapidly" To Get SNG001 Over Line

Read more
20 Jul 2020 20:23

COVID SCIENCE-Multiple vaccine candidates show early promise; inhaled interferon helps severe COVID-19 patients

By Nancy LapidJuly 20 (Reuters) - The following is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.Early tests of COVID-19 ...

Read more
20 Jul 2020 16:55

LONDON MARKET CLOSE: FTSE 100 Lags Despite Encouraging Vaccine News

LONDON MARKET CLOSE: FTSE 100 Lags Despite Encouraging Vaccine News

Read more
20 Jul 2020 11:54

Synairgen Shares Soar On Positive Trial Results For Covid-19 Treatment

Synairgen Shares Soar On Positive Trial Results For Covid-19 Treatment

Read more
20 Jul 2020 09:10

UPDATE 2-Synairgen soars after drug shows promise in COVID-19 cases

* Shares hit all-time high on Monday* Company's drug cuts risk of severe COVID-19 by 79%* Some researchers caution on enthusiasm (Recasts, adds comment from CEO and academic expert)By Aakash BJuly 20 (Reuters) - Synairgen shares rose almost sixfold...

Read more
20 Jul 2020 09:10

REFILE-UPDATE 2-Synairgen soars after drug shows promise in COVID-19 cases

(Refiles to correct spelling in the media identifier)* Shares hit all-time high on Monday* Company's drug cuts risk of severe COVID-19 by 79%* Some researchers caution on enthusiasmBy Aakash BJuly 20 (Reuters) - Synairgen shares rose almost sixfold ...

Read more
20 Jul 2020 09:10

UPDATE 1-Synairgen shares soar as drug shows lower risk of severe COVID-19 cases

(Adds details on the trial, shares)July 20 (Reuters) - Synairgen Plc said on Monday its drug helped reduce the risk of severe cases in hospitalised patients with COVID-19, according to data from a trial of more than 100 people in the United Kingdo...

Read more
20 Jul 2020 07:56

Europe open: Stocks reverse early losses, healthcare leads

(Sharecast News) - Stocks have recovered from early selling following news that European Union leaders meeting in Brussels had made progress on the terms for a reconstruction fund.

Read more
20 Jul 2020 07:56

Synairgen's drug shows reduced risk of severe disease in COVID-19 patients

July 20 (Reuters) - Synairgen Plc said on Monday its drug helped reduce the risk of developing severe diseases in hospitalised COVID-19 patients, according to data from a trial of more than 100 people in the United Kingdom.The trial, which used in...

Read more
20 Jul 2020 07:20

Synairgen treatment reduces risk of 'severe' Covid-19 by 79%

(Sharecast News) - Synairgen's Covid-19 treatment sharply reduced the risk of patients developing severe forms of the illness provoked by the novel coronavirus, clinical trials showed.

Read more
22 Jun 2020 16:09

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
18 Jun 2020 17:59

IN BRIEF: Synairgen Expands Home Setting Trial Of Inhaled SNG001

IN BRIEF: Synairgen Expands Home Setting Trial Of Inhaled SNG001

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.